Over the last few years, therapeutic mRNA has attracted considerable attention in its prospects to change the paradigm of how infectious diseases are treated. Our company is one of the prominent players in this field and as such, we are actively involved in the development of therapeutic mRNA. We hope to work with you further on advancing your research with our uniquely designed therapies that meet the needs of addressing the complications associated with infectious diseases.
Therapeutic mRNA for Infectious Diseases
mRNA therapy or therapeutic mRNA is important in the cellular gene expression process. In contrast to small molecules drugs that will act on the target pathogen or different components of the pathogen, therapeutic mRNA acts by directing cells to make certain proteins that inhibit the infectious agents. As therapeutic mRNA utilizes the cell's natural l biology, it provides a robust versatile platform for the creation of targeted therapies against infectious diseases.
Fig. 1 mRNA-based modalities for infectious disease management. (Zhang M, et al., 2023)
How Does Therapeutic mRNA Work?
The process through which therapeutic mRNA acts involves quite a few steps and the ultimate result of these steps is the synthesis of the desired proteins.
| Steps |
Description |
| Delivery of mRNA |
The synthesized mRNA molecules are delivered into the target cells. These mRNA molecules contain the genetic code that encodes the desired therapeutic protein. |
| Recognition of mRNA |
Once inside the cell, the mRNA is recognized by the cellular machinery and transported to the ribosomes. |
| Translation of mRNA |
The ribosomes read the mRNA sequence and synthesize the corresponding protein. This protein can be an antibody, enzyme, or any other therapeutic agent designed to fight a specific infectious agent. |
| Action of Therapeutic Proteins |
Once produced, the therapeutic protein performs its intended function, such as neutralizing pathogens, modulating immune responses, or disrupting viral replication. |
Market Analysis of Therapeutic mRNA
The surge in the use of mRNA technologies paired with improved manufacturing and delivery technologies has led to the growth of mRNA therapies. According to a market study mRNA therapies became a 5.1 billion dollar market in the United States in 2023 and it has been projected to grow up to twelve point eighteen billion dollars by 2033, translating to a compound annual growth rate of nine point one percent from 2023 to 2024.
Challenges in Therapeutic mRNA Development
As of now, there are only a few approved therapeutic mRNA drugs in the area of infectious diseases because of various hurdles to the development of mRNA therapeutics. The key underlying challenges are as listed below:
- mRNA delivery
- Immunogenicity and inflammatory response
- Stability and half-life
- Dose optimization and toxicity
- Tissue-specific targeting
- Manufacturing scalability and cost
Our Services
In light of the enormous promise of therapeutic mRNA in treating infectious diseases, our company is focused on solving the problems with the development of therapeutic mRNA. The objective is to develop and take forward mRNA therapies that are groundbreaking and have the potential to alter the treatment paradigms in the scope of infectious diseases.
How Do We Develop Small Molecule Drugs?
Target Identification
Understanding the biology and pathogenesis of the disease, our scientists assist in selecting disease targets and specific mRNA molecules for targeting modulation.
In Vitro Transcription
The mRNA sequence is produced through an enzyme mediated mechanism via in vitro transcription (IVT). After this, the mRNA is thoroughly purified to ensure its quality, integrity or continuity.
Preclinical Testing
During the preclinical research phase, the formulated mRNA is assessed for safety, efficacy, and pharmacokinetic properties, in appropriate in vitro and animal studies.
mRNA Sequence Design
We shall focus on enhancing the mRNA sequence. In this part, we are aiming to make the mRNA to be more stable, efficient in translation, and more likely to have a lower immunogenic reaction.
Formulation and Delivery System Development
Achieving suitable safe and effective mRNA delivery with long term stability as well as improving tissue targeting shall be sought by optimizing the composition and the mRNA delivery system.
Applicable Disease Types
Our organization is making strides in the mRNA mediated therapeutics domain pushing forward the development of advanced solutions to combat various pathogens. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Zhang M, Hussain A, Yang H, et al. mRNA-based modalities for infectious disease management[J]. Nano research, 2023, 16(1): 672-691.
- Qin S, Tang X, Chen Y, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases[J]. Signal transduction and targeted therapy, 2022, 7(1): 166.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
